German Financing – WBTS Forum http://wbts-forum.org// Mon, 26 Apr 2021 08:03:34 +0000 en-US hourly 1 https://wordpress.org/?v=5.7.1 http://wbts-forum.org//wp-content/uploads/2021/04/default1.png German Financing – WBTS Forum http://wbts-forum.org// 32 32 Informa merges its financial intelligence activity with Novantas http://wbts-forum.org//informa-merges-its-financial-intelligence-activity-with-novantas/ http://wbts-forum.org//informa-merges-its-financial-intelligence-activity-with-novantas/#respond Mon, 26 Apr 2021 06:35:04 +0000 http://wbts-forum.org//informa-merges-its-financial-intelligence-activity-with-novantas/ Globe Newswire Transactions related to the share buyback program Company Announcement COPENHAGEN, Denmark; April 26, 2021 – Genmab A / S (Nasdaq: GMAB). On February 23, 2021, Genmab announced the launch of a share buyback program to mitigate dilution due to the exercise of warrants and to honor our commitments under our unit program. ‘restricted […]]]>


Globe Newswire

Transactions related to the share buyback program

Company Announcement COPENHAGEN, Denmark; April 26, 2021 – Genmab A / S (Nasdaq: GMAB). On February 23, 2021, Genmab announced the launch of a share buyback program to mitigate dilution due to the exercise of warrants and to honor our commitments under our unit program. ‘restricted actions. The share buyback program is expected to be completed by June 30, 2021 and includes up to 200,000 shares. The following transactions were executed as part of the program from April 19, 2021 to April 23, 2021: Number of shares Average price (DKK) Total value (DKK) Cumulative at last announcement 115,000 237,524,833 April 19, 20211,8002,206,243,971,232 April 20, 20211,6002,217,643,548,22421 April 202122 April, 20211,600 1,5002,233,892,281,413,574,2243,422,11523 April 20211,4002,262,103,166,940 Total7,900 17,682,735 Accumulated under the program 122,900 255,207,568 The Details of each transaction are included as an appendix to this announcement. Following these transactions, Genmab holds 225,877 treasury shares, corresponding to 0.34% of the total capital and voting rights. The share buyback program is implemented in accordance with Regulation (EU) No 596/2014 (“MAR”) and Commission Delegated Regulation (EU) 2016/1052, also known as the “Safe Harbor Regulation”. “. Further details on the terms of the share buyback program can be found in our corporate announcement no. 11 of February 23, 2021. About Genmab Genmab is an international biotechnology company whose primary goal is to improve the lives of cancer patients. Founded in 1999, Genmab is the creator of several approved therapeutic antibodies which are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next generation antibody technologies, expertise in antibody biology, translational research and data science and strategic partnerships. To create new therapies, Genmab uses its next generation antibody technologies, which are the result of its collaborative corporate culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of engineered antibody candidates, including bispecific T-cell engaging agents and next-generation immune checkpoint modulators, effector-enhanced antibodies, and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark, with locations in Utrecht, the Netherlands, Princeton, New Jersey, the United States and Tokyo, Japan. For more information, please visit Genmab.com. Contact: Marisol Peron, Senior Vice President, Global Investor Relations & Communications T: +1 609 524 0065; E: mmp@genmab.com For Investor Relations: Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com This company announcement contains forward-looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward-looking statements. Actual results or performance may differ materially from future results or performance expressed or implied in such statements. Important factors that could cause our actual results or performance to vary materially include, but are not limited to, risks associated with preclinical and clinical product development, uncertainties associated with the results and conduct of clinical trials, including unforeseen safety issues, uncertainties related to the product. manufacturing, lack of market acceptance of our products, inability to manage growth, competitive environment in relation to our industry and markets, inability to attract and retain suitably qualified personnel, inapplicability or lack of protection of our patents and rights, our relationships with affiliated entities, technological changes and developments that may render our products or technologies obsolete, and other factors. For a more in-depth discussion of these risks, please refer to the risk management sections of Genmab’s most recent financial reports, available at www.genmab.com and to the risk factors included in Genmab’s latest annual report on form 20-F and other documents filed. with the United States Securities and Exchange Commission (SEC), available at www.sec.gov. Genmab assumes no obligation to update or revise any forward-looking statements in this company announcement or to confirm such statements to reflect subsequent events or circumstances after the date of publication or in connection with actual results, unless the law requires it. Genmab A / S and / or its subsidiaries own the following brands: Genmab®; the Y-shaped Genmab® logo; Genmab in combination with the Y-shaped Genmab® logo; HuMax®; DuoBody®; DuoBody in combination with the DuoBody® logo; HexaBody®; HexaBody in combination with the HexaBody® logo; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® and Kesimpta® are trademarks of Novartis AG or its subsidiaries. DARZALEX® and DARZALEX FASPRO® are registered trademarks of Janssen Pharmaceutica NV. TEPEZZA® is a trademark of Horizon Therapeutics plc. Company announcement no. 33CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A / SKalvebod Brygge 431560 Copenhagen VDenmark Attachments 210426_CA33_Transactions in connection with SBBP 26 April 210426_CA33_Appendix Specification for April 19-23



Source link

]]>
http://wbts-forum.org//informa-merges-its-financial-intelligence-activity-with-novantas/feed/ 0
Food Ingredient Maker Tate & Lyle Plans to Divide Its Healthcare Business http://wbts-forum.org//food-ingredient-maker-tate-lyle-plans-to-divide-its-healthcare-business/ http://wbts-forum.org//food-ingredient-maker-tate-lyle-plans-to-divide-its-healthcare-business/#respond Mon, 26 Apr 2021 06:18:08 +0000 http://wbts-forum.org//food-ingredient-maker-tate-lyle-plans-to-divide-its-healthcare-business/ Globe Newswire Transactions related to the share buyback program Company Announcement COPENHAGEN, Denmark; April 26, 2021 – Genmab A / S (Nasdaq: GMAB). On February 23, 2021, Genmab announced the launch of a share buyback program to mitigate dilution due to the exercise of warrants and to honor our commitments under our unit program. ‘restricted […]]]>


Globe Newswire

Transactions related to the share buyback program

Company Announcement COPENHAGEN, Denmark; April 26, 2021 – Genmab A / S (Nasdaq: GMAB). On February 23, 2021, Genmab announced the launch of a share buyback program to mitigate dilution due to the exercise of warrants and to honor our commitments under our unit program. ‘restricted actions. The share buyback program is expected to be completed by June 30, 2021 and includes up to 200,000 shares. The following transactions were executed as part of the program from April 19, 2021 to April 23, 2021: Number of shares Average price (DKK) Total value (DKK) Cumulative at last announcement 115,000 237,524,833 April 19, 20211,8002,206,243,971,232 April 20, 20211,6002,217,643,548,22421 April 202122 April, 20211,600 1,5002,233,892,281,413,574,2243,422,11523 April 20211,4002,262,103,166,940 Total7,900 17,682,735 Accumulated under the program 122,900 255,207,568 The Details of each transaction are included as an appendix to this announcement. Following these transactions, Genmab holds 225,877 treasury shares, corresponding to 0.34% of the total capital and voting rights. The share buyback program is implemented in accordance with Regulation (EU) No 596/2014 (“MAR”) and Commission Delegated Regulation (EU) 2016/1052, also known as the “Safe Harbor Regulation”. “. Further details on the terms of the share buyback program can be found in our corporate announcement no. 11 of February 23, 2021. About Genmab Genmab is an international biotechnology company whose primary goal is to improve the lives of cancer patients. Founded in 1999, Genmab is the creator of several approved therapeutic antibodies which are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next generation antibody technologies, expertise in antibody biology, translational research and data science and strategic partnerships. To create new therapies, Genmab uses its next generation antibody technologies, which are the result of its collaborative corporate culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of engineered antibody candidates, including bispecific T-cell engaging agents and next-generation immune checkpoint modulators, effector-enhanced antibodies, and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark, with locations in Utrecht, the Netherlands, Princeton, New Jersey, the United States and Tokyo, Japan. For more information, please visit Genmab.com. Contact: Marisol Peron, Senior Vice President, Global Investor Relations & Communications T: +1 609 524 0065; E: mmp@genmab.com For Investor Relations: Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com This company announcement contains forward-looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward-looking statements. Actual results or performance may differ materially from future results or performance expressed or implied in such statements. Important factors that could cause our actual results or performance to vary materially include, but are not limited to, risks associated with preclinical and clinical product development, uncertainties associated with the results and conduct of clinical trials, including unforeseen safety issues, uncertainties related to the product. manufacturing, lack of market acceptance of our products, inability to manage growth, competitive environment in relation to our industry and markets, inability to attract and retain suitably qualified personnel, inapplicability or lack of protection of our patents and rights, our relationships with affiliated entities, technological changes and developments that may render our products or technologies obsolete, and other factors. For a more in-depth discussion of these risks, please refer to the risk management sections of Genmab’s most recent financial reports, available at www.genmab.com and to the risk factors included in Genmab’s latest annual report on form 20-F and other documents filed. with the United States Securities and Exchange Commission (SEC), available at www.sec.gov. Genmab assumes no obligation to update or revise any forward-looking statements in this company announcement or to confirm such statements to reflect subsequent events or circumstances after the date of publication or in connection with actual results, unless the law requires it. Genmab A / S and / or its subsidiaries own the following brands: Genmab®; the Y-shaped Genmab® logo; Genmab in combination with the Y-shaped Genmab® logo; HuMax®; DuoBody®; DuoBody in combination with the DuoBody® logo; HexaBody®; HexaBody in combination with the HexaBody® logo; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® and Kesimpta® are trademarks of Novartis AG or its subsidiaries. DARZALEX® and DARZALEX FASPRO® are registered trademarks of Janssen Pharmaceutica NV. TEPEZZA® is a trademark of Horizon Therapeutics plc. Company announcement no. 33CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A / SKalvebod Brygge 431560 Copenhagen VDenmark Attachments 210426_CA33_Transactions in connection with SBBP 26 April 210426_CA33_Appendix Specification for April 19-23



Source link

]]>
http://wbts-forum.org//food-ingredient-maker-tate-lyle-plans-to-divide-its-healthcare-business/feed/ 0
Novatek shareholders approve $ 11 billion in external financing for Arctic LNG 2 http://wbts-forum.org//novatek-shareholders-approve-11-billion-in-external-financing-for-arctic-lng-2/ http://wbts-forum.org//novatek-shareholders-approve-11-billion-in-external-financing-for-arctic-lng-2/#respond Mon, 26 Apr 2021 05:23:04 +0000 http://wbts-forum.org//novatek-shareholders-approve-11-billion-in-external-financing-for-arctic-lng-2/ Shareholders of Russia’s second-largest gas producer, Novatek, have approved $ 11 billion in external financing for the Arctic LNG 2 project on which Novatek has pledged its 60% stake in the project as collateral. The approval came on April 23 at the company’s annual general meeting of shareholders. Making the announcement, Novatek CEO Leonid Mikhelson […]]]>


Shareholders of Russia’s second-largest gas producer, Novatek, have approved $ 11 billion in external financing for the Arctic LNG 2 project on which Novatek has pledged its 60% stake in the project as collateral.

The approval came on April 23 at the company’s annual general meeting of shareholders. Making the announcement, Novatek CEO Leonid Mikhelson said the responsibility for fundraising would be divided in three ways between Russia, China and the tandem of Japan and Europe acting together.

The $ 21 billion project, which received final investment approval in 2019, is expected to start production in 2023 as Novatek expands its LNG exports east and west along the coast now navigable arctic of Russia.

Arctic LNG 2 will reach full capacity of nearly 20 mtpa in 2026, according to the company.

Novatek has a 60% stake in the project, with the remaining 40% being split equally between France’s Total, China National Petroleum Corporation, China’s CNOOC and the Japan Arctic LNG consortium, made up of Mitsui & Co. and the state-owned JOGMEC, officially known as Japan Oil, Gas, and Metals National Corp.

In April, Novatek said it would pledge the 60% stake as collateral for long-term funding, according to Reuters.

Financial media reports conducted by Reuters said in September that the project had already attracted enough international capital to cover almost all of the $ 11 billion sought. Quoting a document first cited by Reuters, S&P Global reported that “the national investment bank and credit agency Bpifrance SA has offered $ 700 million in credit financing; China Development Bank and German bank Euler Hermes would offer a $ 5 billion facility and a $ 300 million covered facility, respectively.

“Other state-backed institutions would have included the Japanese Bank for International Cooperation with a $ 2.5 billion facility, Italian SACE with a $ 1 billion covered facility, and an anonymous Russian bank with $ 1 billion, $ 5 billion, ”S&P Global reported, citing Reuters figures.

Russian state bank Sberbank approved funding of up to 3 billion euros ($ 3.5 billion) in January, Reuters wrote.

At the end of February, Novatek signed an agreement with Chinese group Shenergy to deliver more than 3 million tonnes of LNG to terminals in China over 15 years, as the Russian gas producer continued to align buyers with the intention of expand its presence in the Asia-Pacific region. Region.

“Our LNG business strategy is to diversify our customer base and target end consumers in the rapidly growing Asia-Pacific region,” Mikhelson said in a statement released at the time. “The Chinese market is one of the key regions of our LNG marketing strategy, and we plan to further increase our supplies of liquefied natural gas there.”

In January, the Russian Arctic-class LNG carrier Christophe de Margerie made the very first round trip along the Northern Kara Sea Sea Route to China, proving that navigation is possible all year round and giving Russia the opportunity to set attractive prices for its LNG exports.

Russia’s largest independent gas producer, Novatek entered the global LNG market by launching the Yamal LNG project in 2017. The upstream activities of the company are concentrated mainly in the Yamal-Nenets Autonomous Region, which is the largest natural gas production area in the world, accounting for about 80% of Russia’s natural gas production and about 15% of global gas production.

In the first quarter of 2021, Novatek produced 158.1 million BOE, including 20.15 Gcm of natural gas and 3,129 thousand tonnes of liquids (gas condensate and crude oil). This represents a 5.3% increase in total hydrocarbons produced (BOE) in the first quarter of 2021 compared to the first quarter of 2020, according to a press release from the company.

Novatek said capital spending on the 19.8 mtpa LNG project will reach $ 21.3 billion. Arctic LNG 2 is expected to start its first train in 2023; the second and third trains will launch in 2024 and 2026 respectively, according to the company’s website.



Source link

]]>
http://wbts-forum.org//novatek-shareholders-approve-11-billion-in-external-financing-for-arctic-lng-2/feed/ 0
From vaccines to PPE, US pledges to help Covid after violent reaction http://wbts-forum.org//from-vaccines-to-ppe-us-pledges-to-help-covid-after-violent-reaction/ http://wbts-forum.org//from-vaccines-to-ppe-us-pledges-to-help-covid-after-violent-reaction/#respond Sun, 25 Apr 2021 21:33:00 +0000 http://wbts-forum.org//from-vaccines-to-ppe-us-pledges-to-help-covid-after-violent-reaction/ WASHINGTON: The United States said on Sunday it was rushing into therapies, rapid diagnostic test kits, ventilators and personal protective equipment (PPE) to help treat patients with Covid-19 and protect frontline health workers in India after fierce criticism of its lukewarm response to the terrible pandemic crisis unfolding in the country. The United States is […]]]>


WASHINGTON: The United States said on Sunday it was rushing into therapies, rapid diagnostic test kits, ventilators and personal protective equipment (PPE) to help treat patients with Covid-19 and protect frontline health workers in India after fierce criticism of its lukewarm response to the terrible pandemic crisis unfolding in the country.
The United States is also “seeking options to urgently deliver oxygen production and related supplies,” the White House National Security Council said in a statement.
The United States will send raw materials for vaccines and step up financial assistance for the production of Covid-19 vaccines, joining European countries to help stem the world’s largest increase in cases.
The equipment necessary for the production of Covishield has been obtained and “will be immediately made available for India,” Emily Horne, spokeswoman for US National Security Advisor Jake Sullivan, said in a statement.
The announcements arrived more than 12 hours after two top Biden administration officials – Sullivan and Secretary of State Antony Blinken – have vowed Washington will deploy additional support and supplies to help India meet the growing challenge of Covid-19 which some experts say could shut the world off.
“Our hearts are with the Indian people in the midst of the appalling Covid-19 epidemic. We are working closely with our partners in the Indian government and will quickly deploy additional support to the Indian people and health heroes in India, ”Blinken tweeted on Saturday evening after Washington, particularly the Biden-Harris dispensation, had been trolled and torn. on social media for his lukewarm response to India’s plight, highlighted in graphic stories and US media visuals. “The United States is deeply concerned about the severe outbreak of COVID in India. We are working tirelessly to deploy more supplies and support to our friends and partners in India as they courageously fight this pandemic. More very soon, ”Sullivan continued in a tweet a few minutes later.
In a statement released Sunday morning, the White House said, Sullivan spoke by phone with his counterpart Ajit Doval and affirmed America’s solidarity with India – “the two countries with the highest number of cases. of Covid in the world ”.
“Building on the seven-decade health partnership between the United States and India – including the battles against smallpox, polio and HIV – they decided that India and the United States would continue to fight together against the global Covid-19 pandemic. Just as India sent aid to the United States when our hospitals were under stress at the start of the pandemic, the United States is determined to help India when needed, ”the statement said.
The NSC statement says the US Development Finance Corporation (DFC) is also funding a substantial expansion of the manufacturing capacity of BioE, the vaccine maker in India, allowing it to produce at least one billion doses of Covid-19 vaccines per the end of 2022.

In addition, the United States is deploying an expert team of public health advisers from the Center for Disease Control (CDC) and USAID to work closely with the United States Embassy, ​​health departments. of India and the staff of the Indian Epidemic Intelligence Service. USAID will also work quickly with CDC to support and accelerate the mobilization of emergency resources available to India through the Global Fund, he added.
“We spoke today with National Security Advisor Ajit Doval about the surge in Covid cases in India and have agreed to stay in close contact over the next few days. The United States stands in solidarity with the Indian people and we are deploying more supplies and resources, ”Sullivan tweeted shortly before the detailed statement, before which the narrative of Americans offering simple words dominated social discourse, even in as dozens of activists and public figures. urged the administration to rush needed emergency aid, including its vaccine surplus.
“Send them those damn vaccines.” We, the taxpayers, paid for this research no Pfizer, et al. Release the patents and let others make the vaccines, ”read a message from a US citizen.

Democratic lawmakers have also joined the chorus. “We must free up our stock of AstraZeneca vaccines now. In India alone, nearly 350,000 cases of Covid-19 have been reported today. When people in India and elsewhere are in desperate need of help, we can’t let vaccines sit in a warehouse, we have to get them where they will save lives, ”tweeted Illinois Congressman Raja Krishnamoorthi .
Some experts had warned that Washington’s nonchalant response was causing it to lose hard-earned public support in India, as even China and Pakistan, not to mention Russia and the EU, stepped up to help New Delhi. Strong criticism has also been leveled at Vice President Kamala Harris, who has remained silent on the crisis in the country of her legacy – as has President Biden.

“I would like to hear our Indian Half Vice President of the United States, @VP @KamalaHarris, talk soon about the # COVID19 crisis in India and how we can help them. Hope she can speak soon, ”tweeted epidemiologist Eric Feigl-Ding, who warns that unless New Delhi immunizes 10 million people a day, the death toll could exceed one million. here August. Pressure on the Biden administration to send its excess vaccine stock to India first and, more broadly, to calm down on intellectual property issues specific to the Covid vaccine, has come amid reports of ‘a drop in vaccination in the United States.

According to one account, about 5 million people, 8% of the American population, who received the first vaccine from the Pfizer or Moderna vaccines, chose not to participate in the second vaccine, believing they were sufficiently protected. Some people fear side effects that would be more serious than the first time. Many vaccination centers are closing or reporting low participation rates.
Besides the United States, several other countries have reached out to India with aid and assistance to aid the country in its fight against the massive surge in coronavirus cases. The British government announced on Sunday that more than 600 units of vital medical equipment would be sent to India. Other promising countries for assistance are Israel, the EU, Germany, France and the UK, among others. Russia and Singapore have already sent aid.

German Chancellor Angela Merkel said in a tweet on Sunday: “… Germany stands in solidarity with India and is urgently preparing a support mission.” “The EU and its Member States will do everything possible to support India at this difficult time,” said Ugo Astuto, European Union Ambassador to India and Bhutan.
Janez Lenarcic, the European Emergency Response Coordinator, informed on Sunday that the EU had activated its Civil Protection Mechanism to help India tackle the Covid crisis.
(With contributions from Indrani Bagchi and agencies)





Source link

]]>
http://wbts-forum.org//from-vaccines-to-ppe-us-pledges-to-help-covid-after-violent-reaction/feed/ 0
Credit Suisse shareholders demand dismissal of chief risk officer after two scandals http://wbts-forum.org//credit-suisse-shareholders-demand-dismissal-of-chief-risk-officer-after-two-scandals/ http://wbts-forum.org//credit-suisse-shareholders-demand-dismissal-of-chief-risk-officer-after-two-scandals/#respond Sun, 25 Apr 2021 21:00:11 +0000 http://wbts-forum.org//credit-suisse-shareholders-demand-dismissal-of-chief-risk-officer-after-two-scandals/ Some of Credit Suisse’s major shareholders will try to remove the risk-oversight member of the board of directors, in protest against two scandals that have cost the bank and its clients billions and tarnished its reputation. Andreas Gottschling – a 53-year-old German who has chaired the risk committee since 2018, earning $ 1 million in […]]]>


Some of Credit Suisse’s major shareholders will try to remove the risk-oversight member of the board of directors, in protest against two scandals that have cost the bank and its clients billions and tarnished its reputation.

Andreas Gottschling – a 53-year-old German who has chaired the risk committee since 2018, earning $ 1 million in annual fees – has been criticized after the Swiss bank lost at least $ 4.7 billion following the collapse of the family office Archegos Capital.

It came shortly after Credit Suisse had to suspend $ 10 billion in supply chain finance funds linked to controversial financier Lex Greensill, whose insolvency could cost clients up to $ 3 billion. of the lender. The bank was forced to raise $ 1.9 billion to consolidate its capital and canceled investor payments.

David Herro, vice president of Harris Associates, who claims to own 10.25% of the shares, said, “It’s the job of the director to represent shareholders and oversee management. . . Not only should Mr Gottschling be dismissed, but I am actually surprised, in light of current events, that he has not already resigned. “

Herro added that he hoped the arrival of a new chairman – former Lloyds Bank chief executive António Horta-Osório – on April 30 would lead to a board overhaul with more banking expertise. recruited.

Harris will be joined by the Ethos Foundation, which represents 200 Swiss pension funds holding between 3 and 5 percent of the lender.

“Our customers are really angry with what happened,” said Vincent Kaufmann, CEO of Ethos. “The other members of the risk committee haven’t been around for very long, so we’ll give them a better chance. [Gottschling] took over in 2018 as president. This now requires a change. “

The Norwegian oil fund also said on Sunday it would vote against the re-election of Gottschling, along with five other board members, including the main independent director, Severin Schwan. The world’s largest sovereign wealth fund held 3.43% of the shares at the end of last year, according to its most recent disclosure.

Credit Suisse and Gottschling declined to comment.

Last week influential proxy advisor Glass Lewis advised shareholders to vote against Gottschling. He said the Greensill and Archegos scandals “cast significant doubt on the effectiveness of the board’s oversight of the company’s risk and control framework. . . Gottschling holds the ultimate responsibility ”.

However, his proxy counterpart ISS did not advise investors to oppose the board member.

Even with Norges’ backing, it’s unclear whether Harris and Ethos can muster enough support to topple Gottschling. Last year, Herro led a public campaign backed by Ethos and hedge funds Silchester International Investors and Eminence Capital to remove President Urs Rohner and keep former CEO Tidjane Thiam in his role.

He failed. Thiam resigned, the president was re-elected and continued until the end of his term. Rohner said at the time that other major shareholders, including BlackRock, had supported him more and that investor turmoil was “not something that worries me very much.”

Gottschling started his career as a quantitative analyst at Deutsche Bank and also worked for McKinsey and as Risk Director at Erste Bank. He is also a director of Deutsche Börse.

As a director, he participated in multiple conference calls on the risks presented by Greensill last year. They were in part motivated by stories from FT revealing that SoftBank was using Credit Suisse’s supply chain finance funds to funnel hundreds of millions of dollars to struggling businesses it owned.

In the end, Gottschling sided with those who believed Greensill was a valuable entrepreneurial client worth continuing to do business with, according to people with first-hand knowledge of the matter.

While SoftBank’s circular fundraising plan was halted, SCF funds linked to Greensill then grew to $ 10 billion. Gottschling was also a supporter of Lara Warner, the former head of risk and compliance at Credit Suisse who was dismissed from her post this month.

Another person close to the bank said Gottschling did not participate in calls about Greensill outside of normal risk committee discussions and did not personally “support” him.

Greensill and Archegos weren’t the only risk management failures during his tenure. In 2018, Credit Suisse lost around $ 60 million after it was allowed to hold a block of shares in clothing company Canada Goose when its stock plunged. A year later, the bank lost $ 200 million when New York hedge fund Malachite Capital went bankrupt.

Additional reporting by Richard Milne



Source link

]]>
http://wbts-forum.org//credit-suisse-shareholders-demand-dismissal-of-chief-risk-officer-after-two-scandals/feed/ 0
Provide free Covid-19 vaccines as health emergency requires public funding, expert says, Health News, ET HealthWorld http://wbts-forum.org//provide-free-covid-19-vaccines-as-health-emergency-requires-public-funding-expert-says-health-news-et-healthworld/ http://wbts-forum.org//provide-free-covid-19-vaccines-as-health-emergency-requires-public-funding-expert-says-health-news-et-healthworld/#respond Sun, 25 Apr 2021 11:22:56 +0000 http://wbts-forum.org//provide-free-covid-19-vaccines-as-health-emergency-requires-public-funding-expert-says-health-news-et-healthworld/ Covid-19 vaccines must be provided free of charge because any public health emergency requires support from public finances, a prominent public health expert advocated on Sunday. Public Health Foundation of India Chairman Professor K Srinath Reddy also said that if “super-propagator” (large gathering of people) events are avoided and everyone starts wearing a mask , […]]]>


Covid-19 vaccines must be provided free of charge because any public health emergency requires support from public finances, a prominent public health expert advocated on Sunday. Public Health Foundation of India Chairman Professor K Srinath Reddy also said that if “super-propagator” (large gathering of people) events are avoided and everyone starts wearing a mask , coronavirus cases will start to descend in India within three weeks.

“Vaccination should be free because any public health emergency, especially an infectious disease, requires public funding to support it as it is considered a public good,” Reddy told PTI in an interview.

“Almost all economists in the world agree on this. So there is no question for a country to charge for a public health emergency … people to buy (vaccines),” he said. -he says.

Reddy was of the opinion that if someone wants the comfort of going to a private hospital of their choice and getting vaccinated, they can pay a service charge there, but the vaccination itself should be free.

As he expects the ongoing second wave of Covid-19 to peak in India, Reddy, who previously headed the Department of Cardiology at the Indian Institute of Medical Sciences (AIIMS), said it depended on .

He said he does not believe in mathematical modeling to estimate and predict cases of Covid-19 infection because it does not take into account that India has both rural and urban areas which have different transmission rates.

Reddy also added: “I don’t take into account mathematical models that don’t take into account that we have to act. All models are only based on how the virus acts; not how we react. ”

“If we crack down on tomorrow, let’s prevent ‘super-spreader’ events with determination and everyone start wearing a mask outside, within three weeks you will start to see the cases decrease,” he said. declared.

“On the other hand, if you don’t do this and if you do it inefficiently, it can go on for several weeks.”

When asked if there would be a third wave of COVID-19 in India, Reddy said it could happen because even though the vaccination program is going very well, the virus can still stay with us under a softer shape and come back again.

Otherwise, other variants of the virus could emerge and constitute a third wave, said Reddy, who has been involved in several major international and national research studies, having trained in cardiology and epidemiology.

But he said it wasn’t fair to worry only about the third wave – whether it’s coming or not.

“If it’s not this virus, another virus may come. There may be the first wave of another virus. You have to strengthen your public systems and your hospital systems to support that,” Reddy said, who obtained a master’s degree in science. (Epidemiology) from McMaster University (Hamilton, Canada).

On COVID-19 case management, Reddy, who is currently an Assistant Professor of Epidemiology at Harvard and is also an Assistant Professor at the Rollins School of Public Health, Emory University and Honorary Professor of Medicine at the University of Sydney said a large number of those infected can still be treated at home and that would reduce pressure on hospitals.

According to him, proper advice on how to take care of oneself at home should be provided to everyone through local community networks and mass media.

Primary health care centers can use citizen-volunteers to monitor home care people with oximeter and, if necessary, measure their blood pressure, and arrange emergency transport arrangements in advance. in case of deterioration of their state of health.

Hospitals that may have beds should be identified so that patients do not have to run from post to post.

The government should publish clear opinions on drugs for the treatment of Covid-19 infection, Reddy said.

He said drugs like Remdesivir have been taken off the WHO list because they have not proven to be helpful.

But there is a huge over-prescription of this drug and the “payoff” is going on.

“So the government should state unequivocally that this is not a drug that is approved,” Reddy said.



Source link

]]>
http://wbts-forum.org//provide-free-covid-19-vaccines-as-health-emergency-requires-public-funding-expert-says-health-news-et-healthworld/feed/ 0
Germany loses ground in funding for startups http://wbts-forum.org//germany-loses-ground-in-funding-for-startups/ http://wbts-forum.org//germany-loses-ground-in-funding-for-startups/#respond Sun, 25 Apr 2021 10:06:00 +0000 http://wbts-forum.org//germany-loses-ground-in-funding-for-startups/ Germany has lost ground to its main European competitors in investments for startups during the coronavirus pandemic, analysts said. Last year, the volume of investor funding fell 15% to just under 5.3 billion euros ($ 6.4 billion), while France and Britain were able to increase their financing, according to a study by the audit and […]]]>


Germany has lost ground to its main European competitors in investments for startups during the coronavirus pandemic, analysts said.

Last year, the volume of investor funding fell 15% to just under 5.3 billion euros ($ 6.4 billion), while France and Britain were able to increase their financing, according to a study by the audit and consulting firm EY.

Startups in France received cash injections of 5.2 billion euros, an increase of 3.4%. Britain extended its lead despite Brexit, and companies there received € 13.9 billion, a quarter more than in 2019, as the number of funding rounds doubled.

The table is similar in the ranking of individual cities: while the startup scene in London alone received an amount of 10.5 billion euros, Paris came in second with 3.9 billion, with Berlin with just over 3 billion euros.

In 2019, the stronghold of German startups is ahead of Paris. Munich is in sixth place.

Neither the pandemic nor Brexit slowed funding for startups across Europe last year, according to the analysis.

Thanks to a record second half-year, total startup funding increased by 17% compared to 2019 to 36.5 billion euros.



Source link

]]>
http://wbts-forum.org//germany-loses-ground-in-funding-for-startups/feed/ 0
Boris Johnson faces allegations over funding to renovate his home http://wbts-forum.org//boris-johnson-faces-allegations-over-funding-to-renovate-his-home/ http://wbts-forum.org//boris-johnson-faces-allegations-over-funding-to-renovate-his-home/#respond Sat, 24 Apr 2021 15:16:08 +0000 http://wbts-forum.org//boris-johnson-faces-allegations-over-funding-to-renovate-his-home/ The Canadian Press The latest figures on COVID-19 in Canada for Sunday, April 25, 2021 The last number of confirmed cases of COVID-19 in Canada at 8:30 p.m. ET on Sunday, April 25, 2021. There are 1,178,986 confirmed cases in Canada. Canada: 1,178,986 confirmed cases (86,229 active, 1,068,792 resolved, 23,965 deaths) *. The total number […]]]>


The Canadian Press

The latest figures on COVID-19 in Canada for Sunday, April 25, 2021

The last number of confirmed cases of COVID-19 in Canada at 8:30 p.m. ET on Sunday, April 25, 2021. There are 1,178,986 confirmed cases in Canada. Canada: 1,178,986 confirmed cases (86,229 active, 1,068,792 resolved, 23,965 deaths) *. The total number of cases includes 13 confirmed cases among repatriated travelers. There were 6,982 new cases on Sunday. The rate of active cases is 226.89 per 100,000 people. In the past seven days, there have been a total of 55,530 new cases. The seven-day moving average of new cases is 7,933. There were 38 new deaths reported on Sunday. In the past seven days, 343 new deaths have been reported. The seven-day moving average of new reported deaths is 49. The seven-day moving average death rate is 0.13 per 100,000 people. The overall death rate is 63.06 per 100,000 people. There were 30,809,196 tests performed. Newfoundland and Labrador: 1,058 confirmed cases (29 active, 1,023 resolved, six deaths). There were two new cases on Sunday. The rate of active cases is 5.55 per 100,000 people. In the past seven days, there have been a total of 15 new cases. The seven-day moving average of new cases is two. No deaths have been reported in the past week. The overall death rate is 1.15 per 100,000 people. There were 238,977 completed tests. Prince Edward Island: 175 confirmed cases (11 active, 164 resolved, zero deaths). There were no new cases on Sunday. The rate of active cases is 6.89 per 100,000 people. In the past seven days, there have been a total of five new cases. The seven-day moving average of new cases is one. No deaths have been reported in the past week. The overall death rate is zero per 100,000 people. There were 139,087 completed tests. Nova Scotia: 2,053 confirmed cases (263 active, 1,723 resolved, 67 deaths). There were 63 new cases on Sunday. The rate of active cases is 26.85 per 100,000 people. In the past seven days, there have been a total of 246 new cases. The seven-day moving average of new cases is 35. No deaths have been reported in the past week. The overall death rate is 6.84 per 100,000 people. There were 495,295 completed tests. New Brunswick: 1,851 confirmed cases (131 active, 1,685 resolved, 35 deaths). There were four new cases on Sunday. The rate of active cases is 16.76 per 100,000 people. In the past seven days, there have been a total of 63 new cases. The seven-day moving average of new cases is nine. There were no new deaths reported on Sunday. In the past seven days, there have been a total of two new deaths reported. The seven-day moving average of new reported deaths is zero. The seven-day moving average death rate is 0.04 per 100,000 people. The overall death rate is 4.48 per 100,000 people. 291,636 tests were performed. Quebec: 344,808 confirmed cases (10,844 active, 323,086 resolved, 10,878 deaths). There were 1,014 new cases on Sunday. The rate of active cases is 126.47 per 100,000 people. In the past seven days, there have been a total of 7,856 new cases. The seven-day moving average of new cases is 1,122. There were nine new deaths reported on Sunday. In the past seven days, 77 new deaths have been reported. The seven-day moving average of new reported deaths is 11. The seven-day moving average death rate is 0.13 per 100,000 people. The overall death rate is 126.86 per 100,000 people. There were 8,076,974 tests performed. Ontario: 445,351 confirmed cases (41,157 active cases, 396,283 resolved, 7,911 deaths). There were 3,947 new cases on Sunday. The rate of active cases is 279.33 per 100,000 people. In the past seven days, there have been a total of 28,356 new cases. The seven-day moving average of new cases is 4,051. There were 24 new deaths reported on Sunday. In the past seven days, 195 new deaths have been reported. The seven-day moving average of new reported deaths is 28. The seven-day moving average death rate is 0.19 per 100,000 people. The overall death rate is 53.69 per 100,000 people. There were 13,679,981 tests performed. Manitoba: 37,598 confirmed cases (2,024 active, 34,607 resolved, 967 deaths). There were 259 new cases on Sunday. The rate of active cases is 146.75 per 100,000 people. In the past seven days, there have been a total of 1,439 new cases. The seven-day moving average of new cases is 206. No new deaths were reported on Sunday. In the past seven days, eight new deaths have been reported. The seven-day moving average of new reported deaths is one. The seven-day moving average death rate is 0.08 per 100,000 people. The overall death rate is 70.11 per 100,000 people. There were 657,128 tests performed. Saskatchewan: 39,932 confirmed cases (2,515 active, 36,942 resolved, 475 deaths). There were 249 new cases on Sunday. The rate of active cases is 213.37 per 100,000 people. In the past seven days, there have been a total of 1,774 new cases. The seven-day moving average of new cases is 253. Two new deaths were reported on Sunday. In the past seven days, a total of 10 new deaths have been reported. The seven-day moving average of new reported deaths is one. The seven-day moving average death rate is 0.12 per 100,000 people. The overall death rate is 40.3 per 100,000 people. There were 748,282 completed tests. Alberta: 181,806 confirmed cases (20,136 active, 159,603 resolved, 2,067 deaths). There were 1,437 new cases on Sunday. The rate of active cases is 455.37 per 100,000 people. In the past seven days, there have been a total of 11,011 new cases. The seven-day moving average of new cases is 1,573. There were three new deaths reported on Sunday. In the past seven days, 27 new deaths have been reported. The seven-day moving average of new reported deaths is four. The seven-day moving average death rate is 0.09 per 100,000 people. The overall death rate is 46.74 per 100,000 people. There were 4,024,151 tests performed. British Columbia: 123,758 confirmed cases (9,065 active, 113,139 resolved, 1,554 deaths). There were no new cases on Sunday. The rate of active cases is 176.1 per 100,000 people. In the past seven days, there have been a total of 4,718 new cases. The seven-day moving average of new cases is 674. No new deaths were reported on Sunday. In the past seven days, 24 new deaths have been reported. The seven-day moving average of new reported deaths is three. The seven-day moving average death rate is 0.07 per 100,000 people. The overall death rate is 30.19 per 100,000 people. There were 2,420,042 tests performed. Yukon: 80 confirmed cases (two active, 77 resolved, one death). There were no new cases on Sunday. The rate of active cases is 4.76 per 100,000 people. In the past seven days, there have been a total of four new cases. The seven-day moving average of new cases is one. No deaths have been reported in the past week. The overall death rate is 2.38 per 100,000 people. There were 8,865 completed tests. Northwest Territories: 48 confirmed cases (five active, 43 resolved, zero deaths). There were no new cases on Sunday. The rate of active cases is 11.07 per 100,000 people. In the past seven days, there have been a total of five new cases. The seven-day moving average of new cases is one. No deaths have been reported in the past week. The overall death rate is zero per 100,000 people. There were 17,577 completed tests. Nunavut: 455 confirmed cases (47 active, 404 resolved, four deaths). There were seven new cases on Sunday. The rate of active cases is 119.43 per 100,000 people. In the past seven days, there have been a total of 38 new cases. The seven-day moving average of new cases is five. No deaths have been reported in the past week. The overall death rate is 10.16 per 100,000 people. There were 11,125 completed tests. This report was automatically generated by the digital data bureau of The Canadian Press and was first published on April 25, 2021. The Canadian Press



Source link

]]>
http://wbts-forum.org//boris-johnson-faces-allegations-over-funding-to-renovate-his-home/feed/ 0
Dispute over Russian pipeline tests Biden’s reach in Europe http://wbts-forum.org//dispute-over-russian-pipeline-tests-bidens-reach-in-europe/ http://wbts-forum.org//dispute-over-russian-pipeline-tests-bidens-reach-in-europe/#respond Sat, 24 Apr 2021 04:31:22 +0000 http://wbts-forum.org//dispute-over-russian-pipeline-tests-bidens-reach-in-europe/ WASHINGTON (AP) – Pressure is growing on President Joe Biden to take action to prevent the completion of a Russian program … WASHINGTON (AP) – Pressure is mounting on President Joe Biden to take action to prevent the completion of a Russian gas pipeline to Europe that many fear will give the Kremlin significant leverage […]]]>


WASHINGTON (AP) – Pressure is growing on President Joe Biden to take action to prevent the completion of a Russian program …

WASHINGTON (AP) – Pressure is mounting on President Joe Biden to take action to prevent the completion of a Russian gas pipeline to Europe that many fear will give the Kremlin significant leverage over partners and American allies. Yet such action could cause a huge break in transatlantic relations, especially with Germany, at a time when Biden has made restoring good ties with Europe a priority.

As the Nord Stream 2 pipeline nears completion, US lawmakers on both sides have stepped up their demands on a White House reluctant to impose further sanctions on Russian and European companies to stop the project. But the chances of that happening seem slim: Germany continues to support the project by increasing its consumption of natural gas, and the pipeline is around 95% complete.

Biden said he opposed the pipeline, which is owned by Russian state-owned Gazprom, with investments from several European companies. He was keen to present himself as tough on Russian President Vladimir Putin while being a staunch supporter of Eastern European countries like Poland and Ukraine who are firmly opposed to him because he sidesteps both.

Of greater concern to the United States, the Russia-Germany pipeline is said to increase Western Europe’s already strong dependence on Russian energy as US-Russian tensions soar over a number of issues, notably Ukraine, electoral interference, cyber-intrusions and repression. opposition figure Alexei Navalny and his supporters.

At the same time, the administration is seeking broad European support, in particular from Germany, the continent’s economic powerhouse, for its planned withdrawal from Afghanistan, measures to combat climate change and efforts to counter it. China’s increasingly global claim. It is not clear whether sanctions targeting companies in Germany and elsewhere would undermine efforts to advance those goals and mend the relationships that were frayed during Donald Trump’s presidency.

On Wednesday, the Senate Foreign Relations Committee unanimously approved a law that would require the administration to impose sanctions on 20 companies involved in financing and construction of the pipeline or explain why they deserve exemptions. In January, the Trump administration hit several Russian companies and ships with sanctions for their involvement, but Biden did not expand the list.

The bill was sponsored by the administration’s vocal critic, Senator Ted Cruz, R-Texas. But he also garnered the support of some of Biden’s strongest supporters of Democratic foreign policy in the Senate, such as committee chairman Bob Menendez of New Jersey, Chris Coons of Delaware, and Jeanne Shaheen of New Hampshire.

“I think right now, as we see Putin trying to eliminate his biggest opposition leader, Navalny, in prison, the best move we can make is shut down the Nord Stream 2 pipeline, if we want to get his attention, ”Shaheen mentioned.

Democrats agreed to back the sanctions after Republicans vowed to drop opposition to two of Biden’s top State Department candidates. Biparty support suggests the administration will struggle to ignore it. Biden was once stung by critics in February for failing to expand the Trump administration’s sanctions.

“We share a comprehensive attitude towards Nord Stream 2 with a lot of people on Capitol Hill, and this is the position that this is a bad deal,” State Department spokesman Ned Price said Thursday. “We will continue to do everything we can, including in accordance with the legislation already in force, to oppose its construction and completion.”

But the administration has yet to take a position on the new legislation, which congressional aides on both sides of the aisle say has a good chance of being passed. That would give Biden 15 days from the crossing date to decide whether or not to hit the 20 companies and ships with penalties.

The sanctions – which would apply to German, Russian, Polish and Austrian entities – would freeze their assets, prevent them from doing international business and could affect their leaders.

Even if Biden opposes the legislation, he will face another delay in action in mid-May when the State Department is due to submit an update to Congress on the administration’s compliance with previous laws. aimed at protecting European energy security which demand sanctions against unspecified companies involved in the construction of the gas pipeline which bypasses both Poland and Ukraine.

On Tuesday, Chancellor Angela Merkel defended Germany’s cooperation with Russia on Nord Stream 2. She noted that Russian gas is already flowing freely in Europe along other routes, including the existing Nord Stream 1 gas pipeline under the Baltic Sea to Germany.

“I would like to stress that the gas delivered via Nord Stream 2, which is not yet circulating, is no worse than the gas from Nord Stream 1, the one which crosses Ukraine and the one which crosses Turkey from Russia”. Said Merkel.

Copyright © 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.



Source link

]]>
http://wbts-forum.org//dispute-over-russian-pipeline-tests-bidens-reach-in-europe/feed/ 0
Turkey is developing broader crypto regulation, says Cenbank chief http://wbts-forum.org//turkey-is-developing-broader-crypto-regulation-says-cenbank-chief/ http://wbts-forum.org//turkey-is-developing-broader-crypto-regulation-says-cenbank-chief/#respond Fri, 23 Apr 2021 19:37:32 +0000 http://wbts-forum.org//turkey-is-developing-broader-crypto-regulation-says-cenbank-chief/ Bloomberg Selling Almost Useless Signals in the Unchartable Stock Market 2021 (Bloomberg) – If you’ve bailed out from the Bollinger Bands, escaped relative strength, or headed the market directional indicator in 2021, you’ve paid for it. investors doing anything other than buying have done them a disservice this year. In fact, when applied to the […]]]>


Bloomberg

Selling Almost Useless Signals in the Unchartable Stock Market 2021

(Bloomberg) – If you’ve bailed out from the Bollinger Bands, escaped relative strength, or headed the market directional indicator in 2021, you’ve paid for it. investors doing anything other than buying have done them a disservice this year. In fact, when applied to the S&P 500, 15 of 22 chart-based indicators tracked by Bloomberg actually lost money, according to back-testing data. And all of them do worse than a simple buy and hold strategy, which is up 11%. Of course, few investors use technical studies in isolation, and even when they do, they do. rarely rely on a single mapping technique to inform their decisions. But if anything, the exercise is reminiscent of the futility of qualifying a market leading in a year when the trip was essentially a one-way ticket. “What we’ve seen this year is a very strong rising market that hasn’t. get a lot of setbacks, ”said Larry Williams, 78, creator of the Williams% R indicator designed to capture a change in a safety’s momentum. A technique-based long-short strategy is down 7.8% since the end of December. “All of the overbought and oversold indicators, mine and anyone else’s, haven’t received a lot of buy signals, but a lot of sell”, it’s hard to resist the temptation to book profits and bail after the S&P 500’s best 12-month rally since the 1930s. Growing anxiety is a mountain of charts signaling a market that has reached its limits. Earlier this month, the index climbed 16% above its 200-day average, a feat that before December had only happened a few times in the past three decades. In addition, the relative strength index of the benchmark has exceeded 70 on a weekly and monthly basis, a sign that the market has risen too far, too fast. sell orders. Hedge funds, for example, came out this month, ditching tech stocks just days before Apple Inc. and Amazon.com Inc. released their financial results. bet of all. The S&P 500 has yet to cut more than 5% this year. At the same time, missing out on the big days is more punitive than ever. Without the first five sessions, the index’s 11% gain drops to 2%. “To try and guess when it’s a good time to be out of the market, you might as well head to Las Vegas,” said Mark Stoeckle, general manager. agent at Adams Funds. “There are just as many risks in doing this.” Bloomberg’s back-testing model buys the S&P 500 when an indicator signals a “buy” and holds it until a “sell” is generated. At that point, the index is sold and a short position is established and held until a buy is triggered. A strategy following RSI signals has fallen 10% this year. The damage occurred as stocks entered the year with frantic momentum that triggered a sell order. The trade has since been in place because the S&P 500 never retreated fast enough and long enough to buy flash. The moving average convergence / divergence indicator – better known as MACD – suffered a loss of 9.8%. Five of the nine trading signals the model produced were buys, and four of them lost money. In addition, the four brief recommendations were the losers. That is the cost of betting against momentum in a market where the S&P 500 has already eclipsed the average Wall Street strategist’s year-end target. conditions were absorbed by the market with more force, or at best a pause, ”said Jeff deGraaf, co-founder of Renaissance Macro Research, which ranked as top technical analyst in Institutional Investor’s annual survey for 11 consecutive years until 2015. “Overbought / Oversold conditions are unnecessary without first defining the underlying market trend. Williams, who has been negotiating since 1962, agrees. Technical analysis tools aren’t broken, he says, but in a bull market as resilient as this one, investors need to use them in the right context. “You have to have a different tool, if you want, for a job you’re doing,” he says. “I have a hammer that can build a house, but if I use the hammer to dig a hole in the ground, it will be really difficult.” For more articles like this, please visit us at bloomberg.com with the most trusted source of business news. © 2021 Bloomberg LP



Source link

]]>
http://wbts-forum.org//turkey-is-developing-broader-crypto-regulation-says-cenbank-chief/feed/ 0